


Research update: Q2 2022

DANCANN PHARMA A/S

Danish DanCann Pharma provides medical cannabis. The company's strategy is to (i) import and distribute cannabis products, (ii) cultivate and export cannabis raw material, and (iii) develop cannabis products as combination medicines.

CEO: Jeppe Rasmussen
 CB: Carsten Trads
 www.dancann.com
 Bloomberg: DANCAN:SS
 Refinitiv Eikon: DANCAN.ST
 Market place: Spotlight DK
 Last share price: DKK 0,813
 Market cap: DKK 26,2m


SHARE PRICE DEVELOPMENT



	12M	YTD	3M	1M
Share perf. (%)	-8,7	-50,8	-1,9	12,3

Source: S&P Capital IQ

VALUATION INTERVAL



	BEAR	BASE	BULL
Value per share	1,7	2,5	5,7
Up-/downside (%)	105	235	601

Source: S&P Capital IQ and Carlsquare Estimates

CARLSQUARE EQUITY RESEARCH

Carlsquare does not take a position in the discussion on whether medical cannabis should be legal or not. The research report is based on information from sources that Carlsquare considers credible.

Fredrik Nilsson
 Associate Equity Analyst

Markus Augustsson
 Head of Equity Research

Rights issue to reach break-even

In the second quarter of 2022, DanCann reported sales just below our estimates. Sales are expected to pick up during the remaining six months. In addition, we adjust our estimates for the agreement with WEECO and a fair value per share of DKK 2.5 (6.7) is calculated. The announced rights issue to fund the company until break-even is reached brings a substantial dilution.

Sales from CannGros are lagging but expected to pick up in Q3-Q4

During the first six months of 2022, DanCann generated net sales of DKK 2.0 million through its wholly owned subsidiary CanGross. Net sales reduced by the cost of sales leaves a gross result of DKK 0.4 million, corresponding to a gross margin of close to 19 per cent. However, drawing any conclusions from this is considered a bit premature.

In the second quarter of 2022, net sales amounted to DKK 0.8 million. That was below our estimates of DKK 1.7 million. However, according to DanCann, sales are expected to increase in the third and fourth quarters. With the lower sales than expected and a higher cost base, EBITDA landed at minus DKK 5.2 million compared to our estimates of minus DKK 2.3 million. Free cash flow amounted to minus 3.7 million, and the cash balance at the end of the period amounted to DKK 5.8 million.

Rights issue to secure commercialization

DanCann has announced that it will raise funding through a rights issue that, if fully subscribed, will provide liquidity of DKK 28.5 million (before related costs). The rights issue aims to secure the financing of the approval of its GMP production facility and execute its commercialisation strategy. The company expects the funds to last until the company has reached break-even.

The rights issue is to be carried through in October 2022. Seventy-seven per cent of the share issue is guaranteed. The share issue is priced at DKK 0.6 per new share, corresponding to a discount of roughly 70 per cent compared to the closing price on August 30, 2022. The share issue will increase the number of shares to 47.45 million if fully subscribed. That means a 37 per cent dilution.

Distribution agreement with WEECO Pharma worth DKK 40m

Leading up to the release of the Q2 report, DanCann announced a new supply agreement. The agreement allows the German company, WEECO Pharma, to distribute DanCann's future THC products on the German market. The agreement with WEECO Pharma adds a fourth partner to the current portfolio of collaborations with Tetra Biopharma, Aeurum Pharma, and Cannasure.

The total value of the agreement with WEECO Pharma is estimated at DKK 40 million over three years. The agreement is conditioned an EU-GMP approval for the products, which is expected to be in place in Q4 2022. The intended sales start is 2023.

Potential upside to the share price

We have adjusted our estimates, given the deal with WEECO Pharma. Assuming a fully subscribed share issue (and the accompanied dilution), we calculate a fair value per share of DKK 2.5 (6.7). That corresponds to an EV/Sales multiple 2023 of 5.9x. Our reference group is currently trading at EV/Sales 2023 of 2.3x. The premium is motivated by the significantly higher expected growth rate than the peers in the reference group.

Key figures (MDKK)

	2020	2021	2022E	2023E	2024E	2025E
Risk-adjusted Net sales	0	1	7	27	102	184
Risk-adjusted EBITDA	-1	-14	-9	-5	4	22
Risk-adjusted EBIT	-1	-15	-10	-6	3	20
Risk-adjusted EBT	-1	-15	-10	-7	1	18
Earning per share	nm.	-0.41	-0.20	-0.09	0.02	0.19
Growth, tot. revenue	nm.	nm.	209%	281%	278%	80%
EBITDA-margin	neg.	neg.	neg.	neg.	4%	12%
EBIT-margin	neg.	neg.	neg.	-20.3%	2.8%	10.8%
EV/Sales	nm.	59.9	7.7	2.0	0.5	0.3
EV/EBITDA (Curr.)	nm.	nm.	nm.	nm.	12,8	2,4

Source: Company information and Carlsquare estimates

Follow-up and comments

For the first six months of 2022, DanCann reported net sales of DKK 2.0 million, with DKK 0.8 million generated in the second quarter. EBIT for the quarter was negative DKK 5.8 million, and our estimates for the quarter were negative DKK 2.3 million.

Commercial build-up as expected

In the second quarter of 2022, DanCann reported net sales of DKK 0.8 million, generated by its wholly owned subsidiary CannGros. The outcome was lower than estimated. However, DanCann believes that sales from CannGros will increase during Q3 and Q4. According to DanCann, the primary cost drivers for the quarter were attributed to developing the production facility, compliance, and general business development. Based on the commercialization trajectory, the current activities of CannGros should have a low effect on share value.

The company continues to show good cost control despite a high business activity level in all segments.

Outcome vs estimates, Q2 2022 (MDKK)

	Q2 22E	Q2 21	Q2 22A	Deviations (%)
Total revenue	1.7	0.0	0.8	-55%
Gross profit	0.6	-1.6	-2.8	-572%
Gross profit margin	40%	neg.	neg.	nm
EBITDA	-2.3	-3.6	-5.2	-126%
EBITDA margin	neg.	neg.	neg.	nm
EBIT	-2.3	-3.8	-5.8	-150%
EBIT margin	neg.	neg.	neg.	nm
EBT	-2.4	-3.8	-6.0	-150%
EPS (SEK)	-0,08	-0,10	-0.16	

Source: Company information and Carlsquare estimates

Free cash flow for the quarter amounted to minus DKK 3.7 million, and the total cash flow landed at DKK minus 3.5 million (-8.6).

Funding until break-even is reached

In our last research update, we stated a continued need for cash in the near term before operational activities would take off. On the same day as the Q2 report was released, DanCann announced its intention to resolve a rights issue. If fully subscribed, the rights issue will strengthen the cash position with DKK 28.5 DKK 21,9 million (before related costs). The rights issue is partially guaranteed to 77 per cent. The issue bear a significant dilution effect as the transaction add roughly 47 million shares to the current number of outstanding shares of 28,4 million shares.

Guaranteed rights to bring in at least DKK 21,9 million.

With the proceeds, DanCann expects to finance the business until the company reaches break-even. According to DanCann, the proceeds will be used to finalize its work towards obtaining the necessary permissions from the Danish Medicines Agency (DMA) and the approval of Biotek Pharm1 (BP1), as well as finalizing the commercialization of its future product portfolio Tetracanoïd, Bidiocanoïd, Mixcanoïd, Varincanoïd, and Bigerolcanoïd.

We see that a capital raise of DKK 28.5 million might be sufficient for an EBITDA-break-even scenario 2024. Given that commercial activity starts to pick-up 2023-2024, DanCann might have to inject funds to sustain operationally.

News of relevance during the first half year

EU-GMP application handed in

After setting up the facility just over a year ago, trial cultivation followed to optimise the manufacturing processes and quality-assure the final products ahead of large-scale production. We believe that the company's competitiveness and success in large depend on the progress of the production facility, especially given that the company's main activity is intended to be the manufacturer of biomaterials and APIs for the European market. Hence, we see the filing on February 9 for EU-GMP approval as a promising step in the right direction. It can be viewed as a signal that DanCann is now moving from a period of test batches to soon be able to capitalise on the development phase it is going through.

EU-GMP = European-Good-Manufacturing-Practice is a minimum standard for pharmaceutical manufacturers aiming to cater for medicines on the European market.

LOI for proprietary products worth at least SEK 37 million

DanCann signed a letter of intent with Aureum Pharma for the exclusive rights to distribute DanCann's proprietary products produced in BIOTECH PHARM1. This agreement does thus put DanCann on the other side of the table. The intended agreement gives Aureum Pharma exclusivity for the Swedish market and binds the companies with a commitment valued at a minimum of SEK 37 million. The expectation for the agreement is that sales can begin in 2023 and run for three years.

Supply agreement with WEECO Pharma worth DKK 40 million

More recently, DanCann announced a new supply agreement regarding their own manufactured products to be distributed by WEECO Pharma in Europe. The agreement is non-exclusive and entails that WEECO will sell and export flower products to WEECO, focusing on THC-products. WEECO will purchase, import, package, market, and distribute.

Value drivers looking ahead

DanCann, like the underlying market, has a short history. Moving forward, we see greater share value reversion opportunities coming from progress in clinical studies and DMA approvals for the Tetra Biopharma product portfolio that DanCann will distribute. The company expects sales of Tetra's products to start in 2022. The soon expected EU-GMP approval for the manufacturing facility also signals that the facility is manufacturing-ready.

EU-GMP approval in current fiscal year

Taking the position as a leading manufacturer of biomaterials and APIs in the future, the EU-GMP approval is crucial. According to DanCann, the approval is expected to be in place around Q4 2022.

Distribution agreement with Tetra BioPharma

The distribution agreement with Tetra gives DanCann exclusive distribution rights for two potential cannabinoid-based pharmaceutical products, Reduvo™, Adversa® and QIXLEEF™ in Denmark, Norway, Sweden, Finland and Germany. The agreement also includes ENJOUCA™, an OTC version of QIXLEEF™ with the same APIs. Reduvo™, Adversa® and QIXLEEF™ are undergoing registrations or clinical trials that may succeed or fail. They are prescription-based and IP-protected, which means that "generic drugs" are not allowed. They are thus a complement to standard GMP medical cannabis products that have not been tested in clinical trials. Ultimately, their commercial value depends on their efficacy, which is not yet established.

CannGros has a pending product application with the DMA

CannGros has a pending product application with the DMA for a product based on oil containing extracts of cannabis. The review process may take time given the detailed and precise requirements. A licensing scenario would significantly reduce risk and be a value driver for DanCann.

Investment case, estimates and valuation

Analysts expect a strong market development in Europe, similar to what has been observed in the US following increased legalisation and reduced stigma of medical cannabis. The local companies that will be able to navigate the various regulatory regimes and meet the required quality standards early in the market growth curve will be at the forefront and capture a larger share of the pie. DanCann is actively working to obtain critical licenses and approvals while diversifying future revenue streams with distribution agreements. The recent communicated share-issue increases the outstanding fleet substantially, when calibrating the capital raise we calculate a fair value per share of DKK 2.5 (6.7).

Investment Case

DanCann has taken shape from a project to an innovative company at the forefront of the fast-changing medical cannabis market for medical purposes.

For the purposes of this analysis, medical cannabis means cannabinoid-based products, prescription or OTC, that are used to treat a medical condition.

- **Demonstrated revenue early in the commercialisation phase.** Founded in 2018, DanCann is one of the first companies approved to participate in the pilot program and is now working with licensing processes to execute its business model. In 2021, the company reported revenues for the first time, thus representing an important milestone.
- **Regulatory tailwinds are picking up in Europe.** At the end of 2021, Danish authorities announced that the pilot program to produce medical cannabis, including raw materials, has become permanent. The permanent permit for cannabis production radically reduces uncertainty for the future of cannabis companies and makes investing in cannabis companies significantly less risky. Germany took the next step at the end of November 2021 when the coalition government announced that cannabis would be legalised in the country for recreational use. This step reinforces the thesis that the level of acceptance of cannabis is gradually increasing in Europe, which is of course, beneficial for DanCann.
- **Distribution agreements targeting several markets stack up future revenues.** Although DanCann is still in the early stage and awaiting the necessary licenses, the team has managed to secure future revenues with multiple distribution agreements to execute on as they navigate the regulatory landscape. DanCann has signed exclusive distribution agreements with Cannasure Therapeutics and Tetra BioPharma, where the agreement with Cannasure target Scandinavia and the agreement with tetra target Scandinavia and Germany. According to DanCann, Tetra BioPharma can provide sales up to DKK 340-410m by 2028. More recently, DanCann has also entered a letter of intent with Aureum Pharma and signed distribution agreement WEECO Pharma.
- **Strategic acquisition accelerates regulatory navigation.** With the acquisition of CannGros in the fourth quarter of 2021, DanCann obtained the necessary licenses to import and distribute medical cannabis, including a proprietary product portfolio in the market. With CannGros licenses, the acquisition marks a major step for DanCann in accelerating its commercialisation trajectory. At the same time, the two companies are expected to complement each other, as CannGros operates primarily as a distributor, and DanCann intends to have its main long-term business in the manufacturing of bio-materials and APIs.


Assumptions and estimates

Strong potential at high risk – Keeping sales estimates

Sales contributed by CannGros have lagged slightly and DanCann believes sales for the affiliate will balance out in Q3 and Q4. Needless to say, DanCann's share value attribution is not in laying in 2022. We keep our sales-estimates for the accumulated pipeline unchanged and add the recently communicated supply agreement with WEECO Pharma to the pipeline. The three-year agreement is worth DKK 40 million and is expected to kick of 2023 with most of the distribution generated in 2024 and 2025.

We continue to believe that sales of cannabis raw material will start in late 2022 and that the revenue in the current fiscal year will mainly come from CannGross' existing sales activities which generate (roughly DKK five million). As delivery expectations are highly dependent on regulatory processes and clinical trials, we routinely risk-adjust the revenue streams in the communicated pipeline.

Risk-adjusted net sales (DKKm)



Source: Company information and Carlsquare estimates


Non-adjusted net sales (DKKm)



Source: Company information and Carlsquare estimates


In our base case, we estimate that the distribution agreement with Tetra Bio-pharma will generate the largest revenues, given the current pipeline. In terms of business segments, import and distribution will be the group's largest revenue source in our scenario, followed by exports of raw materials and APIs. However, there is ample room for these revenue sources to change as DanCann has recently started approaching distributors (Aeum Pharma).

Revenue distribution (%)



Source: Company information and Carlsquare estimates

EBITDA (DKKm) and Margin (%)



Source: Company information and Carlsquare estimates

By the end of 2031, revenues from Tetra BioPharma accounts for half of DanCann's turnover in our current scenario, followed by the CannGross portfolio, which could

generate almost a quarter of the turnover. However, the revenue contributions may change drastically if any of the application processes take longer than expected or if clinical trials in the future distribution portfolio are not approved, e.g. Reduvo Ad-versa and Qixleaf intended for the Danish market. We estimate an EBITDA of DKK minus 9 million (-8) for 2022 and a positive EBITDA- margin around 2024.

Fair value within a range


We value DanCann Pharma at DKK 2.5 per share (6.7) for the next 6-12 months by combining a multiple valuation based on estimated sales in 2023 with a DCF model. That corresponds to an enterprise value (EV) of DKK 158 million (181). DanCann's recently communicated rights issue for bringing in DKK 28 million in cash have significant dilution effect when emitted.

Fair value per share (DKK), base scenario

Multiple valuation (EV/Sales, 2023)	1.2
DCF valuation	3.8
Fair value per share	2.5
Potential up-/downside	197%
Shares outstanding, fully financed, and diluted	75,9
Shareholder value	207
Cash (last rep. Q)	6
Debt (last rep. Q)	0
PV cash from equity financing	28
EV	158

Source: Carlsquare estimates

Fair value per share within an interval (DKK)



Source: Carlsquare estimates

Implicit multiples, Base scenario

	2022P	2023P	2024P	2025P
EV/Sales	23.2x	5.9x	1.5x	0.9x
EV/EBITDA	NM	NM	38.5x	38.5x
EV/EBIT	NM	NM	55.0x	7.9x

Source: Carlsquare estimates

As shown in the table above, our valuation corresponds to an implied 2023 EV/Sales multiple of 5.9x and a 2024 EV/Sales multiple of 1,5x. Our reference group, consisting of companies that primarily grow medical cannabis plants and extract APIs for sale and distribution to manufacturers of medical cannabis-derived products, is currently trading at a median 2023 EV/Sales multiple of 2.3x.

DCF-valuation, Summary of base scenario

DCF valuation		Discount rate		Assumptions	
PV(UFCF)	53.4	Risk-free rate	1.9%	CAGR, 2022-2031	56.1%
PV(TV)	201.5	Market risk premium	6.7%	EBITDA-margin, 2031	19.7%
Enterprise value	255	Size premium	3.0%	EBIT-margin, 2031	18.3%
Net cash(31-Dec)	5.8	Beta	1.2x	Tax rate	20.6%
Shareholder value	261	Req. return on equity	13.5%		
PV(equity financing proceeds)	28			Implied multiples	
Shareholder value, after financing	289	Tax adjust. interest on debt	2.4%	EV/Sales, NTM	nm.
Shares outstanding after financing and dilution	75.9	Leverage	0.0%	EV/Sales 2022	37.5x
Value per share	3.8	WACC	13.5%	EV/EBITDA, NTM	neg.
				EV/EBITDA 2022	neg.
		Company spec. premium	0.0%	EV/EBIT NTM	neg.
		Discount rate	13.5%	EV/EBIT, 2022	neg.

Source: Carlsquare estimates

Below is a sensitivity analysis with the discount rate (Y-axis) and assumed growth rate (X-axis) for calculating the terminal value. Ranging the discount rate between 11.2-15.2 per cent and the long term growth rate between 3-6 per cent results in a value-range between 2,7 -6,8 DKK per share.

Sensitivity analysis (DKK/share)

	3,0%	4,0%	5,0%	6,0%
11,2%	4.8	5.3	5.9	6.8
12,2%	4.1	4.4	4.9	5.5
13,2%	3.5	3.8	4.1	4.6
14,2%	3.1	3.3	3.6	3.9
15,2%	2.7	2.9	3.1	3.3

Discount rate on the Y-axis and growth in perpetuity on the X-axis.

Source: Carlsquare estimates

Below is the multiple valuation. With expected sales of approximately DKK 27 million in 2023 and a WACC of 13.5%, we calculate a value per share of DKK 3.8.

Multiple valuation, base scenario

	HQ	Mcap (SEKm)	EV/Sales, LTM	EV/Sales, 2023P
Trulieve Cannabis Corp.	US	19 898	3.1x	2.3x
Little Green Pharma Ltd	AU	378	6.2x	N.A
Tikun Olam-Cannbit Pharmaceuticals Ltd	IL	237	3.1x	N.A
Tilray Brands, Inc.	CA	15 544	4.0x	2.8x
Stenocare A/S	DK	114	85.0x	N.A
OrganiGram Holdings Inc.	CA	2 405	2.5x	1.1x
Median		1 392	3.6x	2.3x
Average		6 429	17.3x	2.1x


Median	
Median Multiple, 2023	2.3x
Discount	0.0
Applied EV/Sales multiple	2.3x
Expected Sales 2023	26.8
Fair Value EV	61.3x
Discount rate	13.5%
Discount period	0.7
PV (Fair Value EV)	56.4
Cash, last rep. Q	9.3
Interest bearing debt, last. Q	0.0
Shareholder value	65.7
Shares outstanding	75.9
Fair value share price	1.2

Source: Capital IQ and Carlsquare estimates

Valuation range


In the Bull and Bear scenarios, we have used our DCF (perpetual capitalization) model but developed alternative growth and profitability curves to allow for wider spreads in the scenario-outcomes.

Net sales (MDKK), three scenarios



Source: Company information and Carlsquare estimates

EBITDA-margin, three scenarios



Source: Company information and Carlsquare estimates

In the Bull scenario, we model an average annual growth rate (CAGR) of 47.6 per cent between 2024-2027 (42.5 per cent in the Base scenario). This scenario illustrates outcomes of further received distribution agreements additional to the current pipeline. In the bear scenario, we model with an average annual growth rate of 37.9 per cent, painting a scenario of delayed, or lost, product applications.

Risks and challenges

Regulatory and political risks

Even if cultivation is made legal permanently, DanCann's other business models still depend on the Danish pilot programme, which is time-limited and will need to be extended.

The current regulatory environment is largely developing in a favourable direction for DanCann. However, it could quickly swing the other way. The regulatory risk is greater for DanCann than for many other companies involved in traditional drug development.

In this context, the regulation also includes compensation. The market may not develop as favourably as expected if medical cannabis products are not widely included in the various reimbursement schemes.

Financing and other risks

The company depends on retaining and attracting key people. CEO and founder Jeppe Rasmussen have locked in his shareholding in the company for three years, consisting of approximately 21 per cent of the share capital. The market for medical cannabis products is relatively new, which means that staff with valuable experience are scarce.

As the market matures favourably, competition is likely to increase. That may cause downward pressure on margins further down the line, particularly on pre-sales of cannabis materials and APIs. As regards the latter, DanCann intends to focus on rare and new APIs.

Analysts expect continued strong growth as new products enter the market and the clinical evidence base grows. However, future growth in the market is uncertain and possibly not as rapid as expected.

Financial accounts and key figures

Income statement (risk adjusted) (DKKm)

	2020	2021	2022E	2023E	2024E	2025E	2026E	2027E	2028E
Net Sales	0	1	7	27	102	184	217	273	325
COGS	-1	-5	-20	-63	-112	-134	-169	-200	-208
Gross profit	-1	-4	-13	-36	-10	50	49	73	117
Tot. op. exp, excl. COGS & dep. and amort.	-1	-15	-12	-12	-36	-51	-54	-61	-70
EBITDA	-2	-19	-25	-48	-46	0	-6	12	48
Dep. and amort.	0	-1	0	-1	-1	-2	-2	-3	-3
EBIT	-1	-15	-10	-6	3	20	28	41	53
Net finances	-1	-15	-10	-6	2	19	27	40	52
EBT	-2	-30	-20	-11	5	39	55	81	105
Tax	1	3	0	0	0	-4	-6	-8	-11
Net profit/loss	0	-12	-10	-6	2	15	21	32	41
EPS	0,00	-0.41	-0.20	-0.08	0.03	0.20	0.28	0.42	0.54
Shares, EoP		28.5	75.9	75.9	75.9	75.9	75.9	75.9	75.9
Average		28.5	52.2	75.9	75.9	75.9	75.9	75.9	75.9

	2020	2021	2022E	2023E	2024E	2025E	2026E	2027E	2028E
Growth									
Net Sales	nm.	nm.	678%	294%	281%	80%	18%	26%	19%
Gross profit	nm.	0%	40%	203%	457%	81%	17%	25%	20%
EBITDA	neg.	-1340%	32%	47%	184%	426%	38%	47%	28%
EBIT	neg.	-1434%	34%	42%	152%	595%	39%	48%	29%
EBT	neg.	-1154%	32%	44%	138%	779%	41%	49%	29%
Net profit/loss	neg.	-34824%	12%	44%	138%	598%	41%	49%	29%
EPS	neg.	0%	-52%	-62%	-138%	598%	41%	49%	29%
Margins									
Gross profit	nm.	73%	33%	26%	39%	39%	39%	38%	39%
EBITDA margin	neg.	-629%	-134%	-20%	3%	11%	13%	15%	16%
EBIT margin	neg.	-659%	-145%	-21%	2%	10%	12%	15%	16%
EBT margin	neg.	-659%	-145%	-21%	2%	10%	12%	15%	16%
Profit margin	neg.	-510%	-145%	-21%	2%	8%	10%	12%	13%

Source: Company information and Carlsquare estimates

Balance sheet (risk adjusted) (DKKm)

	2020	2021	2022E	2023E	2024E	2025E	2026E
Tot. Intangible assets	0	41	45	48	50	52	54
Tot. Tangible assets	4	10	10	11	13	13	13
Financial non-current assets	0	0	0	0	0	0	0
Tot. Fixed assets	4	51	55	59	63	65	67
Inventories	0	1	5	19	32	38	48
Accounts receivables	1	1	4	13	23	27	34
Other receivables	2	2	2	2	2	2	2
Cash and Cash equivalents	8	14	1	0	7	22	44
Total current assets	18	26	24	54	78	105	146
Sum Assets	69	81	83	117	143	172	216
Share capital	1	6	6	6	6	6	6
Reserve for development costs	23	46	47	63	63	63	63
Retained Earnings	30	19	14	16	31	53	85
Sum Equity	53	71	67	85	100	122	154
Debt to Creditors	0	0	0	0	0	0	0
Total long-term liabilities	0	0	0	0	0	0	0
Leasing liabilities	0	0	0	0	0	0	0
Accounts Payables	3	1	4	10	18	22	27
Corporation tax payable	0	0	0	0	0	0	0
Other current liabilities	11	7	11	20	23	27	34
Total Short Term Debt	15	9	15	31	42	49	62
Total Debt	15	9	15	31	42	49	62
Total Equity and Debt	69	81	83	117	143	172	216
Liquidity	2020	2021	2022E	2023E	2024E	2025E	2026E
Current ratio	120%	304%	161%	174%	187%	212%	237%
Cash ratio	53%	168%	4%	1%	16%	44%	71%
Leverage	2020	2021	2022E	2023E	2024E	2025E	2026E
Net debt(-)/Net cash(+)	11	-2	3	-26	-27	-20	-5
Net debt/EBITDA	NM	NM	NM	NM	NM	NM	NM
Net debt/Equity	NM	0,0x	NM	0,3x	0,3x	0,2x	0,0x
Equity/Total Assets	77%	88%	81%	73%	70%	71%	71%
Efficiency	2020	2021	2022E	2023E	2024E	2025E	2026E
ROA	0.0%	Neg.	Neg.	Neg.	1.5%	8.9%	9.9%
ROE	0.1%	Neg.	Neg.	Neg.	2.4%	13.8%	15.6%
ROIC	Neg.	Neg.	Neg.	Neg.	1.4%	9.2%	11.5%

Source: Company information and Carlsquare estimates

Cash flow (risk adjusted) (DKKm)

	2020	2021	2022E	2023E	2024E	2025E	2026E
CF, operating activities before delta WC	0	-14	-10	-6	2	16	23
Delta operating capital	0	2	-8	-5	-14	-7	-4
CF, Operating Activities	0	-12	-18	-11	-12	9	18
CF, Investing Activities (CAPEX)	0	-32	-4	-4	-6	-4	-4
CF, Financing Activities	0	31	28	30	25	10	0
Cash flow	0	-14	7	15	8	15	14
Cash, BoP	0	21	8	14	29	37	52
Cash, EoP	0	8	14	29	37	52	66
Key ratios	2020	2021	2022E	2023E	2024E	2025E	2026E
CF, Operating Activities/Net Sales	-	-1371%	-261%	-42%	-11%	5%	10%
CF, Operating Activities/EBITDA	0%	25%	39%	3154%	211%	76%	39%

Source: Company information and Carlsquare estimates

Disclaimer

Carlsquare AB, www.carlsquare.se, hereinafter referred to as Carlsquare, conducts business with regard to Corporate Finance and Equity Research in which areas it, among other things, publishes information about companies including analyses. The information has been compiled from sources that Carlsquare considers to be reliable. However, Carlsquare cannot guarantee the accuracy of the information. Nothing written in the analysis should be regarded as a recommendation or invitation to invest in any financial instrument, option or the like. Opinions and conclusions expressed in the analysis are intended only for the recipient.

The content may not be copied, reproduced or distributed to another person without the written approval of Carlsquare. Carlsquare shall not be held responsible for any direct or indirect damage caused by decisions made on the basis of information contained in this analysis. Investments in financial instruments provide opportunities for value increases and profits. All such investments are also subject to risks. Risks vary between different types of financial instruments and combinations of these. Historical returns should not be considered as an indication of future returns.

The analysis is not directed to US persons (as defined in Regulation S of the United States Securities Act and interpreted in the United States Investment Company Act 1940) nor may it be disseminated to such persons. The analysis is also not directed to such natural and legal persons where the distribution of the analysis to such persons would result in or entail a risk of a violation of Swedish or foreign law or constitution.

The analysis is a so-called Commissioned Research Report where the analysed company has signed an agreement with Carlsquare for analysis coverage. The analyses are published on an ongoing basis during the contract period and for a usual fixed remuneration.

Carlsquare may or may not have a financial interest in the subject of this analysis. Carlsquare values the assurance of objectivity and independence and has established procedures for managing conflicts of interest for this purpose.

The analyst Fredrik Nilsson and Markus Augustsson does not own and is not allowed to own shares in the company analysed.